Accendra Health, Inc. (ACH)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-09
$1.07-2.73%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-09
Broken: Primary pillar broken — Revenue near $2.55B to $2.65B in FY26: FY26 revenue guidance $2.45B-$2.55B vs target $2.55B.
Accendra Health aims to generate free cash flow of $90M to $110M in 2026. The company affirms revenue guidance near $2.6B and adjusted EBITDA around $345M. Despite recent revenue declines, management maintains its outlook. Share buybacks signal confidence in future cash flow.
Revenue is expected to decline about 1% next year. Recent earnings and guidance cuts show pressure on profits. Litigation and debt refinancing raise financial risks. Free cash flow remains negative and volatile.
The market expects about -1% revenue growth and has priced in a weak outlook. Our fair value near $21.67 suggests the stock is cheap versus peers. We differ by cautiously watching free cash flow recovery and revenue stabilization.
Breaks if: adjusted EBITDA falls below $335M in FY26
Maintain full-year 2026 financial guidance with revenue between $2.45B-$2.55B and adjusted EBITDA of $300M-$320M, targeting breakeven to slightly positive free cash flow.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a turnaround investment with a focus on improving financial performance. The current thesis state reflects mixed management execution and strong recent results, but the company is still loss-making.
The market seems to have priced in a level of fragility, given the low expectations gap compared to peers. Valuation is considered cheap versus its industry, indicating that some positive developments may not be fully reflected.
Management's commitment to affirming revenue and EBITDA guidance is a key focus, though execution has been mixed. Recent financial performance has shown strength, but the company remains at risk due to its high volatility and loss-making status.
The thesis hinges on management's ability to meet financial targets and the overall performance of the healthcare sector. Key forward scenarios include potential earnings guidance cuts or positive momentum from sector leaders.
The most important moves since the prior daily snapshot.
Valuation rose by 12.3 points (from 55.6 to 67.9).
Mixed, the news cuts both ways. The leadership transition and CEO succession planning is progressing positively. However, the latest earnings miss raises concerns about revenue and guidance issues.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. The company reaffirmed 2026 revenue guidance at $2.45B-$2.55B and adjusted EBITDA at $300M-$320M, with free cash flow expected to be breakeven to slightly positive. The trajectory shows consistent commitment to these financial targets.
“The company is updating its prior financial guidance for the full year 2026, summarized below. Revenue: $2.45 billion - $2.55 billion Adjusted EBITDA: $300 million - $320 million Free cash flow: brea…”
“The company is affirming its prior guidance for net revenue and adjusted EBITDA for the full year 2026.”
Breaks if: material cash flow impairment or credit downgrade from debt/litigation
Breaks if: free cash flow falls below $90M in FY26
Breaks if: revenue falls below $2.55B in FY26
Maintain full-year 2026 financial guidance with revenue between $2.45B-$2.55B and adjusted EBITDA of $300M-$320M, targeting breakeven to slightly positive free cash flow.
Stated as a priority in 2 of last 2 quarters. The company reaffirmed 2026 revenue guidance at $2.45B-$2.55B and adjusted EBITDA at $300M-$320M, with free cash flow expected to be breakeven to slightly positive. The trajectory shows consistent commitment to these financial targets.
“The company is updating its prior financial guidance for the full year 2026, summarized below. Revenue: $2.45 billion - $2.55 billion Adjusted EBITDA: $300 million - $320 million Free cash flow: brea…”
“The company is affirming its prior guidance for net revenue and adjusted EBITDA for the full year 2026.”
In the next 1 to 3 years, ACH's performance will depend on management execution and sector conditions. Not investment advice.